This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
These data sources are known for being highly referenced and usable for specific research activities; further yet, a number of recognizable open sources, along with their identifiers, are considered industry standard resources.
The Orphan Drug Act of 1983 was instrumental in changing the number of orphan drugs approved in the U.S. The law established the Office of Orphan Products Development , providing financial incentives for pharmaceuticalcompanies to develop orphan drugs and making it more viable to invest in orphan drugresearch and development.
Dr. Liu shared his over 30 years of R&D experience in drug development both in the global pharmaceuticalcompanies and world renowned scientific research institutions. Innovent has built an international team with expertise in cutting-edge biological drug development and commercialization.
CMap utilizes gene expression profiles to connect drugs, genes, and diseases, enabling researchers to identify potential repurposing candidates based on their transcriptional signatures. Thalidomide : Initially marketed as a sedative in the late 1950s, thalidomide was withdrawn from the market due to its severe teratogenic effects.
Drug development: addressing complexity and success rates Drug development is a complex and expensive process, requiring multidisciplinary expertise and high-risk financial investments. The major hurdles that pharmaceuticalcompanies face are long lead times, high costs and a low probability of success (PoS).
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content